Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

14.11 +0.49 (+3.60%)
Streaming Delayed Price Updated: 9:41 AM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

< Previous 1 2 3 4 5 6 Next >
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Engages MZ Group for Investor Relations Strategy
Via Investor Brand Network
Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
From Quantum BioPharma
Via GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Engages Enterprise Canada, Empire Market Ventures for PR, Investor Awareness
Via Investor Brand Network
Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM
Via ACCESSWIRE
Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs
From Quantum BioPharma
Via GlobeNewswire
Quantum BioPharma Heads For Best Week Ever — But Most Retail Traders Lament Missing Out On The Surge
The company has attracted heavy attention after its dietary supplement, Unbuzzd, showed that it can reduce blood alcohol concentration rapidly in a clinical trial. 
Via Stocktwits
Which stocks are moving on Thursday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Quantum BioPharma Shares Are Up Over 80%: What's Going On?
Quantum BioPharma shares are surging Thursday after its licensee, Celly Nutrition, engaged a New York investment bank to raise up to $10 million and explore a potential U.S. initial public offering. 
Via Benzinga
On Thursday, there are stocks with unusual volume. Let's take a look.
Let's explore the current happenings on the US markets on Thursday. Below, you'll find the stocks exhibiting unusual volume in today's session. 
Via Chartmill
Thursday's session: top gainers and losers
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Thursday's session: gap up and gap down stocks
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
Dow Edges Higher; US Weekly Jobless Claims Increase
 
Via Benzinga
Topics Stocks
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Licensee Celly Nutrition Pursues $10M Capital Raise and U.S. IPO
Via Investor Brand Network
Topics Initial Public Offering
Which stocks are moving before the opening bell on Thursday?
Wondering what's happening in Thursday's pre-market session? Find an overview in this article. 
Via Chartmill
Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study
From Quantum BioPharma
Via GlobeNewswire
These stocks have an unusual volume in today's session
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
Top movers analysis one hour before the close of the markets on 2025-02-04: top gainers and losers in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Quantum BioPharma Shares Are Up Today: What's Going On?
Shares of Quantum BioPharma Ltd. (NASDAQ: QNTM) are soaring more than 70% on Tuesday after the company announced positive clinical trial results for its dietary supplement, unbuzzd, which accelerates... 
Via Benzinga
Gold Moves Higher; Estée Lauder Shares Slide
 
Via Benzinga
Tuesday's session: top gainers and losers
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
Nasdaq Surges Over 1%; Pfizer Earnings Top Estimates
 
Via Benzinga
Traders are paying attention to the gapping stocks in Tuesday's session.
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Positive Clinical Trial Results for unbuzzd™
Via Investor Brand Network
Quantum BioPharma Stock Soars As Unbuzzd Trial Shows Rapid Fall In Blood Alcohol Levels, Retail Frenzy Ensues
The company said it also led to a 67% reduction in headache severity at four hours and continued to ease cognitive and physical impairment up to eight hours after consumption. 
Via Stocktwits
US Stocks Mixed; PepsiCo Posts Downbeat Sales
 
Via Benzinga
Discover the top movers in Tuesday's pre-market session.
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Quantum BioPharma Stock Is Soaring Tuesday: What's Driving The Action?
Quantum BioPharma Ltd (NASDAQ:QNTM) shares are rising Tuesday after the company announced positive clinical trial results for its unbuzzd dietary supplement. 
Via Benzinga
Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial
Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover 
From Quantum BioPharma
Via GlobeNewswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
Via Investor Brand Network
Quantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation Updates
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.